CN101240013A - 高纯度脂肽、脂肽胶束及其制备方法 - Google Patents
高纯度脂肽、脂肽胶束及其制备方法 Download PDFInfo
- Publication number
- CN101240013A CN101240013A CNA200810087401XA CN200810087401A CN101240013A CN 101240013 A CN101240013 A CN 101240013A CN A200810087401X A CNA200810087401X A CN A200810087401XA CN 200810087401 A CN200810087401 A CN 200810087401A CN 101240013 A CN101240013 A CN 101240013A
- Authority
- CN
- China
- Prior art keywords
- daptomycin
- lipopeptid
- damping fluid
- resin
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 209
- 230000008569 process Effects 0.000 title claims description 17
- 108010028921 Lipopeptides Proteins 0.000 title abstract description 89
- 239000000693 micelle Substances 0.000 title abstract description 85
- 229960005484 daptomycin Drugs 0.000 claims abstract description 568
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 claims abstract description 544
- 108010013198 Daptomycin Proteins 0.000 claims abstract description 535
- 241000958215 Streptomyces filamentosus Species 0.000 claims abstract description 29
- 238000005571 anion exchange chromatography Methods 0.000 claims abstract description 28
- 238000004191 hydrophobic interaction chromatography Methods 0.000 claims abstract description 19
- 239000000872 buffer Substances 0.000 claims abstract description 12
- 239000011347 resin Substances 0.000 claims description 93
- 229920005989 resin Polymers 0.000 claims description 93
- 238000002360 preparation method Methods 0.000 claims description 91
- 150000003839 salts Chemical class 0.000 claims description 73
- 239000012535 impurity Substances 0.000 claims description 68
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 66
- 239000012530 fluid Substances 0.000 claims description 66
- 238000013016 damping Methods 0.000 claims description 64
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 57
- 230000006872 improvement Effects 0.000 claims description 33
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 31
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 29
- 239000002904 solvent Substances 0.000 claims description 27
- 238000001914 filtration Methods 0.000 claims description 25
- 238000004587 chromatography analysis Methods 0.000 claims description 19
- 238000004140 cleaning Methods 0.000 claims description 19
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 16
- 239000004202 carbamide Substances 0.000 claims description 16
- 239000000178 monomer Substances 0.000 claims description 15
- 238000010828 elution Methods 0.000 claims description 11
- 238000005352 clarification Methods 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 9
- 238000000926 separation method Methods 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 4
- 238000011082 depyrogenation Methods 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 44
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 37
- 238000004128 high performance liquid chromatography Methods 0.000 abstract description 31
- 238000000855 fermentation Methods 0.000 abstract description 24
- 230000004151 fermentation Effects 0.000 abstract description 24
- 239000003242 anti bacterial agent Substances 0.000 abstract description 16
- 229940088710 antibiotic agent Drugs 0.000 abstract description 15
- 238000004519 manufacturing process Methods 0.000 abstract description 9
- 238000004458 analytical method Methods 0.000 abstract description 7
- 230000001976 improved effect Effects 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 62
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 27
- 239000000203 mixture Substances 0.000 description 27
- 241000894006 Bacteria Species 0.000 description 25
- 239000000047 product Substances 0.000 description 23
- 235000010633 broth Nutrition 0.000 description 21
- 239000003814 drug Substances 0.000 description 21
- 238000000108 ultra-filtration Methods 0.000 description 21
- 238000011282 treatment Methods 0.000 description 19
- 239000008351 acetate buffer Substances 0.000 description 18
- 239000007853 buffer solution Substances 0.000 description 18
- 239000002502 liposome Substances 0.000 description 18
- 208000015181 infectious disease Diseases 0.000 description 17
- -1 aspartyl group Chemical group 0.000 description 16
- 108010049047 Echinocandins Proteins 0.000 description 15
- 238000005516 engineering process Methods 0.000 description 15
- 230000003115 biocidal effect Effects 0.000 description 14
- 239000003429 antifungal agent Substances 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 13
- 230000018044 dehydration Effects 0.000 description 13
- 238000006297 dehydration reaction Methods 0.000 description 13
- 150000002500 ions Chemical class 0.000 description 13
- 239000007788 liquid Substances 0.000 description 12
- 229940094933 n-dodecane Drugs 0.000 description 12
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 12
- 238000009472 formulation Methods 0.000 description 11
- 235000013372 meat Nutrition 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 210000004379 membrane Anatomy 0.000 description 11
- 125000001402 nonanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 11
- 239000012071 phase Substances 0.000 description 11
- 235000014347 soups Nutrition 0.000 description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000004255 ion exchange chromatography Methods 0.000 description 9
- IIYFAKIEWZDVMP-UHFFFAOYSA-N linear paraffin C13 Natural products CCCCCCCCCCCCC IIYFAKIEWZDVMP-UHFFFAOYSA-N 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000003960 organic solvent Substances 0.000 description 9
- 239000002510 pyrogen Substances 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 8
- 241000191967 Staphylococcus aureus Species 0.000 description 8
- BGHCVCJVXZWKCC-UHFFFAOYSA-N Tetradecane Natural products CCCCCCCCCCCCCC BGHCVCJVXZWKCC-UHFFFAOYSA-N 0.000 description 8
- YCOZIPAWZNQLMR-UHFFFAOYSA-N heptane - octane Natural products CCCCCCCCCCCCCCC YCOZIPAWZNQLMR-UHFFFAOYSA-N 0.000 description 8
- 230000002209 hydrophobic effect Effects 0.000 description 8
- 239000003456 ion exchange resin Substances 0.000 description 8
- 229920003303 ion-exchange polymer Polymers 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 238000004237 preparative chromatography Methods 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 238000001223 reverse osmosis Methods 0.000 description 8
- 229960001866 silicon dioxide Drugs 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- ORZVJBWXRAJYHN-RWDRXURGSA-N (3S)-3-[[(2S)-4-amino-2-[[(2S)-2-(decanoylamino)-3-(1H-indol-3-yl)propanoyl]amino]-4-oxobutanoyl]amino]-4-[[(5R,8S,11S,14R,15S,21S,24S,27R,30S)-11-[2-(2-aminophenyl)-2-oxoethyl]-21-(3-aminopropyl)-24-(carboxymethyl)-8-[(2R)-1-carboxypropan-2-yl]-5-(hydroxymethyl)-14,27-dimethyl-3,6,9,12,16,19,22,25,28,32,33-undecaoxo-13-oxa-1,4,7,10,17,20,23,26,29-nonazabicyclo[28.2.1]tritriacontan-15-yl]amino]-4-oxobutanoic acid Chemical compound CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)c2ccccc2N)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CN2C(=O)C[C@H](NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)C2=O)[C@H](C)CC(O)=O ORZVJBWXRAJYHN-RWDRXURGSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- 238000007710 freezing Methods 0.000 description 6
- 230000008014 freezing Effects 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 235000020061 kirsch Nutrition 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 241000193998 Streptococcus pneumoniae Species 0.000 description 5
- 239000006035 Tryptophane Substances 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 239000002260 anti-inflammatory agent Substances 0.000 description 5
- 229940121363 anti-inflammatory agent Drugs 0.000 description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003792 electrolyte Substances 0.000 description 5
- 239000012149 elution buffer Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 238000007918 intramuscular administration Methods 0.000 description 5
- 238000003825 pressing Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 229960004799 tryptophan Drugs 0.000 description 5
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 5
- MEIRRNXMZYDVDW-MQQKCMAXSA-N (2E,4E)-2,4-hexadien-1-ol Chemical compound C\C=C\C=C\CO MEIRRNXMZYDVDW-MQQKCMAXSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241000606768 Haemophilus influenzae Species 0.000 description 4
- 206010035664 Pneumonia Diseases 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 108010059993 Vancomycin Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000010564 aerobic fermentation Methods 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- JHVAMHSQVVQIOT-MFAJLEFUSA-N anidulafungin Chemical compound C1=CC(OCCCCC)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=O)N[C@@H]2C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C2)[C@@H](C)O)[C@H](O)[C@@H](O)C=2C=CC(O)=CC=2)[C@@H](C)O)=O)C=C1 JHVAMHSQVVQIOT-MFAJLEFUSA-N 0.000 description 4
- 238000005349 anion exchange Methods 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 235000008504 concentrate Nutrition 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 229940047650 haemophilus influenzae Drugs 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 239000012266 salt solution Substances 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 229960003165 vancomycin Drugs 0.000 description 4
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 3
- 244000215068 Acacia senegal Species 0.000 description 3
- 235000006491 Acacia senegal Nutrition 0.000 description 3
- AFWTZXXDGQBIKW-UHFFFAOYSA-N C14 surfactin Natural products CCCCCCCCCCCC1CC(=O)NC(CCC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)O1 AFWTZXXDGQBIKW-UHFFFAOYSA-N 0.000 description 3
- 244000025254 Cannabis sativa Species 0.000 description 3
- 108010015899 Glycopeptides Proteins 0.000 description 3
- 102000002068 Glycopeptides Human genes 0.000 description 3
- 108010006464 Hemolysin Proteins Proteins 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- 239000000232 Lipid Bilayer Substances 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000191940 Staphylococcus Species 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- UPADRKHAIMTUCC-OWALTSPQSA-N [(2r,3r,4r,6s)-6-[(2r,2'r,3's,3ar,4r,4'r,6s,7s,7ar)-6-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4s,5s,6s)-6-[(3ar,3'as,4r,6's,7r,7'r,7as,7'as)-7-(2,4-dihydroxy-6-methylbenzoyl)oxy-7'-hydroxyspiro[3a,6,7,7a-tetrahydro-[1,3]dioxolo[4,5-c]pyran-4,2'-4,6,7,7a-tetrahydro-3a Chemical compound O([C@@H]1CO[C@]2([C@@H]3OCO[C@H]31)O[C@H]1CO[C@H]([C@@H]([C@@H]1O2)O)O[C@@H]1O[C@@H]([C@H]([C@H](O)[C@@H]1OC)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@H]([C@@]3(C)O[C@]4(O[C@H](C)[C@@H](O[C@@H]5O[C@H](C)[C@@H](OC(=O)C=6C(=C(Cl)C(O)=C(Cl)C=6C)OC)[C@H](O[C@@H]6O[C@@H](C)[C@H](OC)[C@](C)(C6)[N+]([O-])=O)C5)[C@H](O)C4)O[C@@H]3[C@@H](C)O2)O)[C@@H](OC)[C@@H](C)O1)O)COC)C(=O)C1=C(C)C=C(O)C=C1O UPADRKHAIMTUCC-OWALTSPQSA-N 0.000 description 3
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 3
- 229940126575 aminoglycoside Drugs 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229940009098 aspartate Drugs 0.000 description 3
- BQFCCCIRTOLPEF-UHFFFAOYSA-N chembl1976978 Chemical compound CC1=CC=CC=C1N=NC1=C(O)C=CC2=CC=CC=C12 BQFCCCIRTOLPEF-UHFFFAOYSA-N 0.000 description 3
- 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 235000011194 food seasoning agent Nutrition 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000003228 hemolysin Substances 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000002798 polar solvent Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- NJGWOFRZMQRKHT-UHFFFAOYSA-N surfactin Natural products CC(C)CCCCCCCCCC1CC(=O)NC(CCC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)O1 NJGWOFRZMQRKHT-UHFFFAOYSA-N 0.000 description 3
- NJGWOFRZMQRKHT-WGVNQGGSSA-N surfactin C Chemical compound CC(C)CCCCCCCCC[C@@H]1CC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)O1 NJGWOFRZMQRKHT-WGVNQGGSSA-N 0.000 description 3
- 229960003250 telithromycin Drugs 0.000 description 3
- LJVAJPDWBABPEJ-PNUFFHFMSA-N telithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@@H]([C@]2(OC(=O)N(CCCCN3C=C(N=C3)C=3C=NC=CC=3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@@]1(C)OC)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O LJVAJPDWBABPEJ-PNUFFHFMSA-N 0.000 description 3
- 239000012049 topical pharmaceutical composition Substances 0.000 description 3
- 238000002525 ultrasonication Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical class O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 2
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 2
- NMARPFMJVCXSAV-UHFFFAOYSA-N 5-[(3,5-diethoxy-4-pyrrol-1-ylphenyl)methyl]pyrimidine-2,4-diamine Chemical compound C=1C(OCC)=C(N2C=CC=C2)C(OCC)=CC=1CC1=CN=C(N)N=C1N NMARPFMJVCXSAV-UHFFFAOYSA-N 0.000 description 2
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241001464890 Anaerococcus prevotii Species 0.000 description 2
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 241001464894 Blautia producta Species 0.000 description 2
- 0 CC(C*)C(C(N)=O)NC(C(CO)N)=O Chemical compound CC(C*)C(C(N)=O)NC(C(CO)N)=O 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 241000193163 Clostridioides difficile Species 0.000 description 2
- 241000193468 Clostridium perfringens Species 0.000 description 2
- 108010065152 Coagulase Proteins 0.000 description 2
- 241001517041 Corynebacterium jeikeium Species 0.000 description 2
- 239000004278 EU approved seasoning Substances 0.000 description 2
- 241001657508 Eggerthella lenta Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241001468179 Enterococcus avium Species 0.000 description 2
- 241000194032 Enterococcus faecalis Species 0.000 description 2
- 241000186588 Erysipelatoclostridium ramosum Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000192016 Finegoldia magna Species 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000186779 Listeria monocytogenes Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- 241001464887 Parvimonas micra Species 0.000 description 2
- 241000192035 Peptostreptococcus anaerobius Species 0.000 description 2
- 206010062255 Soft tissue infection Diseases 0.000 description 2
- 206010041925 Staphylococcal infections Diseases 0.000 description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 description 2
- 241000191984 Staphylococcus haemolyticus Species 0.000 description 2
- 241000192087 Staphylococcus hominis Species 0.000 description 2
- 241001147691 Staphylococcus saprophyticus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241000193985 Streptococcus agalactiae Species 0.000 description 2
- 241000194049 Streptococcus equinus Species 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 2
- 108010053950 Teicoplanin Proteins 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 241000193462 [Clostridium] innocuum Species 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 125000003162 alpha-aspartyl group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- FXKSEJFHKVNEFI-GCZBSULCSA-N amikacin disulfate Chemical compound [H+].[H+].[H+].[H+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O FXKSEJFHKVNEFI-GCZBSULCSA-N 0.000 description 2
- 229960004909 aminosalicylic acid Drugs 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 150000003851 azoles Chemical class 0.000 description 2
- 229960003644 aztreonam Drugs 0.000 description 2
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- PPKJUHVNTMYXOD-PZGPJMECSA-N c49ws9n75l Chemical compound O=C([C@@H]1N(C2=O)CC[C@H]1S(=O)(=O)CCN(CC)CC)O[C@H](C(C)C)[C@H](C)\C=C\C(=O)NC\C=C\C(\C)=C\[C@@H](O)CC(=O)CC1=NC2=CO1.N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2C[C@@H](CS[C@H]3C4CCN(CC4)C3)C(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O PPKJUHVNTMYXOD-PZGPJMECSA-N 0.000 description 2
- 229960004755 ceftriaxone Drugs 0.000 description 2
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 2
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000011210 chromatographic step Methods 0.000 description 2
- 238000011097 chromatography purification Methods 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- KFGZZMBROBJWRH-KTNYHBKCSA-N ecomytrin Chemical compound C([C@@]1([C@H]2CC3)C)CN4CC[C@H]1[C@]4(O)C[C@H]2[C@H]1[C@@]3(C)[C@H]2CC(=O)O[C@H]2C1 KFGZZMBROBJWRH-KTNYHBKCSA-N 0.000 description 2
- 229940032049 enterococcus faecalis Drugs 0.000 description 2
- 239000003344 environmental pollutant Substances 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000000855 fungicidal effect Effects 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000000867 larynx Anatomy 0.000 description 2
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 2
- 229960003907 linezolid Drugs 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 229940115931 listeria monocytogenes Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 229960000282 metronidazole Drugs 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- 238000001471 micro-filtration Methods 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 229960000808 netilmicin Drugs 0.000 description 2
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- VHFGEBVPHAGQPI-MYYQHNLBSA-N oritavancin Chemical compound O([C@@H]1C2=CC=C(C(=C2)Cl)OC=2C=C3C=C(C=2O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2O[C@@H](C)[C@H](O)[C@@](C)(NCC=4C=CC(=CC=4)C=4C=CC(Cl)=CC=4)C2)OC2=CC=C(C=C2Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]2C(=O)N[C@@H]1C(N[C@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@@H](O)[C@H](C)O1 VHFGEBVPHAGQPI-MYYQHNLBSA-N 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- 239000003973 paint Substances 0.000 description 2
- 229940074571 peptostreptococcus anaerobius Drugs 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000003495 polar organic solvent Substances 0.000 description 2
- 231100000719 pollutant Toxicity 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 108010071077 quinupristin-dalfopristin Proteins 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- HJHVQCXHVMGZNC-JCJNLNMISA-M sodium;(2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoate Chemical compound [Na+].O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C([O-])=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C HJHVQCXHVMGZNC-JCJNLNMISA-M 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 229940037649 staphylococcus haemolyticus Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229940030998 streptococcus agalactiae Drugs 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229940020707 synercid Drugs 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229960001608 teicoplanin Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 2
- 229960003231 thioacetazone Drugs 0.000 description 2
- 229960002898 threonine Drugs 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- JWYOAMOZLZXDER-UHNVWZDZSA-N (1r,2s)-2-azaniumylcyclopentane-1-carboxylate Chemical compound N[C@H]1CCC[C@H]1C(O)=O JWYOAMOZLZXDER-UHNVWZDZSA-N 0.000 description 1
- HMHQWJDFNVJCHA-BTZKOOKSSA-N (2s)-2-[[(5r,8s)-8-[[(2s,3r)-1-[(2s)-2-amino-3-hydroxypropanoyl]-3-hydroxypyrrolidine-2-carbonyl]amino]-14,16-dihydroxy-13-methyl-7,11-dioxo-10-oxa-3-thia-6-azabicyclo[10.4.0]hexadeca-1(16),12,14-triene-5-carbonyl]amino]propanoic acid Chemical compound N([C@H]1COC(=O)C2=C(C)C(O)=CC(O)=C2CSC[C@H](NC1=O)C(=O)N[C@@H](C)C(O)=O)C(=O)[C@@H]1[C@H](O)CCN1C(=O)[C@@H](N)CO HMHQWJDFNVJCHA-BTZKOOKSSA-N 0.000 description 1
- VQGRPWQSNMEBHD-YQQOEYNUSA-N (3S)-3,6-diamino-N-[(3S,6Z,9S,12S,15S)-3-[(4S,6R)-2-amino-4-hydroxy-1,4,5,6-tetrahydropyrimidin-6-yl]-6-[(carbamoylamino)methylidene]-9,12-bis(hydroxymethyl)-2,5,8,11,14-pentaoxo-1,4,7,10,13-pentazacyclohexadec-15-yl]hexanamide 3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]propanoic acid sulfuric acid Chemical compound OS(O)(=O)=O.OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O.N1C(=O)\C(=C\NC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)C[C@@H](N)CCCN)CNC(=O)[C@@H]1[C@@H]1NC(N)=N[C@@H](O)C1 VQGRPWQSNMEBHD-YQQOEYNUSA-N 0.000 description 1
- AFIMUUSGRZSMCR-LPZKKVOTSA-N (4r,5s,6s)-3-[(2r,3r)-2-[[[(2s)-2-amino-3-methylbutanoyl]amino]methyl]oxolan-3-yl]sulfanyl-6-[(1r)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid Chemical compound CC(C)[C@H](N)C(=O)NC[C@H]1OCC[C@H]1SC1=C(C(O)=O)N2C(=O)[C@H]([C@@H](C)O)[C@H]2[C@H]1C AFIMUUSGRZSMCR-LPZKKVOTSA-N 0.000 description 1
- PZLOCBSBEUDCPF-YJIVIRPOSA-N (4r,5s,6s)-6-[(1r)-1-hydroxyethyl]-3-[(3s,5s)-5-[(1r)-1-hydroxy-3-(methylamino)propyl]pyrrolidin-3-yl]sulfanyl-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid Chemical compound C1N[C@H]([C@H](O)CCNC)C[C@@H]1SC1=C(C(O)=O)N2C(=O)[C@H]([C@@H](C)O)[C@H]2[C@H]1C PZLOCBSBEUDCPF-YJIVIRPOSA-N 0.000 description 1
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
- FLSUCZWOEMTFAQ-PRBGKLEPSA-N (5r,6s)-6-[(1r)-1-hydroxyethyl]-7-oxo-3-[(1r,3s)-1-oxothiolan-3-yl]sulfanyl-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid Chemical compound S([C@@H]1[C@H](C(N1C=1C(O)=O)=O)[C@H](O)C)C=1S[C@H]1CC[S@@](=O)C1 FLSUCZWOEMTFAQ-PRBGKLEPSA-N 0.000 description 1
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 1
- JLGKQTAYUIMGRK-UHFFFAOYSA-N 1-{2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C2=CC=CC(Cl)=C2SC=1)CN1C=NC=C1 JLGKQTAYUIMGRK-UHFFFAOYSA-N 0.000 description 1
- ZNOVVAJWYUBFMI-JIFFNSBPSA-N 2,2-dimethylpropanoyloxymethyl (4r,5s,6s)-6-[(1r)-1-hydroxyethyl]-4-methyl-7-oxo-3-[(3r)-5-oxopyrrolidin-3-yl]sulfanyl-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(=O)OCOC(=O)C(C)(C)C)=O)[C@H](O)C)S[C@H]1CNC(=O)C1 ZNOVVAJWYUBFMI-JIFFNSBPSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- YZEUHQHUFTYLPH-UHFFFAOYSA-N 2-nitroimidazole Chemical compound [O-][N+](=O)C1=NC=CN1 YZEUHQHUFTYLPH-UHFFFAOYSA-N 0.000 description 1
- VCOPTHOUUNAYKQ-DAOVIKHBSA-N 3,6-diamino-n-[[(2s,5s,8z,11s,15s)-15-amino-11-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;3,6-diamino-n-[[(2s,5s,8z,11s,15s)-15-a Chemical compound N1C(=O)\C(=C\NC(N)=O)NC(=O)[C@H](CNC(=O)CC(N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1C1NC(=N)NCC1.N1C(=O)\C(=C\NC(N)=O)NC(=O)[C@H](CNC(=O)CC(N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1C1NC(=N)NCC1 VCOPTHOUUNAYKQ-DAOVIKHBSA-N 0.000 description 1
- HCXJFMDOHDNDCC-UHFFFAOYSA-N 5-$l^{1}-oxidanyl-3,4-dihydropyrrol-2-one Chemical group O=C1CCC(=O)[N]1 HCXJFMDOHDNDCC-UHFFFAOYSA-N 0.000 description 1
- MPORYQCGWFQFLA-ONPDANIMSA-N 7-[(7s)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1r,2s)-2-fluorocyclopropyl]-4-oxoquinoline-3-carboxylic acid;trihydrate Chemical compound O.O.O.C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1.C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 MPORYQCGWFQFLA-ONPDANIMSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 206010053555 Arthritis bacterial Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical group C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108010065839 Capreomycin Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241001262170 Collinsella aerofaciens Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229940050191 DB-289 Drugs 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000186394 Eubacterium Species 0.000 description 1
- 229930188253 Everninomicin Natural products 0.000 description 1
- 229930187800 Fusacandin Natural products 0.000 description 1
- 241000605986 Fusobacterium nucleatum Species 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010093096 Immobilized Enzymes Proteins 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- VNRAPWIEXZLTKI-UHFFFAOYSA-N LL15G256gamma Natural products N1C(=O)C(CCC(O)=O)NC(=O)C(C)C(C(C)CCCCCCCC)OC(=O)C(CO)NC(=O)C1C(=O)C1=CNC2=CC=CC=C12 VNRAPWIEXZLTKI-UHFFFAOYSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- ROAIXOJGRFKICW-UHFFFAOYSA-N Methenamine hippurate Chemical compound C1N(C2)CN3CN1CN2C3.OC(=O)CNC(=O)C1=CC=CC=C1 ROAIXOJGRFKICW-UHFFFAOYSA-N 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 108010021062 Micafungin Proteins 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 241000192001 Pediococcus Species 0.000 description 1
- 241000192013 Peptoniphilus asaccharolyticus Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- VRDIULHPQTYCLN-UHFFFAOYSA-N Prothionamide Chemical compound CCCC1=CC(C(N)=S)=CC=N1 VRDIULHPQTYCLN-UHFFFAOYSA-N 0.000 description 1
- 241001290151 Prunus avium subsp. avium Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 108010052859 Sch 40832 Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 241000194023 Streptococcus sanguinis Species 0.000 description 1
- 241000194054 Streptococcus uberis Species 0.000 description 1
- 241001312524 Streptococcus viridans Species 0.000 description 1
- 108010034396 Streptogramins Proteins 0.000 description 1
- 101100244894 Sus scrofa PR39 gene Proteins 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 238000000333 X-ray scattering Methods 0.000 description 1
- PKHFEGZZONAJBZ-COWAJZTFSA-N [(2s,3s,4r,5r,6r)-5-[(2s,3r,4s,5r,6r)-6-[[(2e,4z)-deca-2,4-dienoyl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-2-[2,4-dihydroxy-6-(hydroxymethyl)phenyl]-3-hydroxy-6-(hydroxymethyl)oxan-4-yl] (2e,4e)-7-hydroxy-2,8-dimethyldeca-2,4-dienoate Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](COC(=O)\C=C\C=C/CCCCC)O[C@H]1O[C@H]1[C@H](OC(=O)C(\C)=C\C=C\CC(O)C(C)CC)[C@@H](O)[C@H](C=2C(=CC(O)=CC=2O)CO)O[C@@H]1CO PKHFEGZZONAJBZ-COWAJZTFSA-N 0.000 description 1
- ITBLPDDJTHGYAL-QBRWPTABSA-N [3',4,6-trihydroxy-6'-(hydroxymethyl)-5'-[3,4,5-trihydroxy-6-[[(2e,4e,6e)-octa-2,4,6-trienoyl]oxymethyl]oxan-2-yl]oxyspiro[1h-2-benzofuran-3,2'-oxane]-4'-yl] (2e,4e,8e,10e)-7-hydroxy-8,14-dimethylhexadeca-2,4,8,10-tetraenoate Chemical compound CCC(C)CC\C=C\C=C(/C)C(O)C\C=C\C=C\C(=O)OC1C(O)C2(C3=C(O)C=C(O)C=C3CO2)OC(CO)C1OC1OC(COC(=O)\C=C\C=C\C=C\C)C(O)C(O)C1O ITBLPDDJTHGYAL-QBRWPTABSA-N 0.000 description 1
- 241000186561 [Clostridium] clostridioforme Species 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- FBCLKBXYZRAXNA-PDIPHZEPSA-N aculeacin A Chemical class C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCCCCCCCCC)[C@H](O)CC(N)=O)=CC=C(O)C=C1 FBCLKBXYZRAXNA-PDIPHZEPSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229960003348 anidulafungin Drugs 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 125000003164 beta-aspartyl group Chemical group 0.000 description 1
- MRMBZHPJVKCOMA-YJFSRANCSA-N biapenem Chemical compound C1N2C=NC=[N+]2CC1SC([C@@H]1C)=C(C([O-])=O)N2[C@H]1[C@@H]([C@H](O)C)C2=O MRMBZHPJVKCOMA-YJFSRANCSA-N 0.000 description 1
- 229960003169 biapenem Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960000662 carumonam Drugs 0.000 description 1
- UIMOJFJSJSIGLV-JNHMLNOCSA-N carumonam Chemical compound O=C1N(S(O)(=O)=O)[C@H](COC(=O)N)[C@@H]1NC(=O)C(=N/OCC(O)=O)\C1=CSC(N)=N1 UIMOJFJSJSIGLV-JNHMLNOCSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- DASYMCLQENWCJG-XUKDPADISA-N cefetamet pivoxil Chemical compound N([C@@H]1C(N2C(=C(C)CS[C@@H]21)C(=O)OCOC(=O)C(C)(C)C)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 DASYMCLQENWCJG-XUKDPADISA-N 0.000 description 1
- 229950000726 cefetamet pivoxil Drugs 0.000 description 1
- XAKKNLNAJBNLPC-MAYKBZFQSA-N cefluprenam Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)/C=C/C[N+](C)(CC)CC(N)=O)C([O-])=O)C(=O)C(=N/OCF)\C1=NSC(N)=N1 XAKKNLNAJBNLPC-MAYKBZFQSA-N 0.000 description 1
- 229950001334 cefluprenam Drugs 0.000 description 1
- ZINFAXPQMLDEEJ-GFVOIPPFSA-N cefoselis Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CN1C=CC(=N)N1CCO ZINFAXPQMLDEEJ-GFVOIPPFSA-N 0.000 description 1
- 229950001580 cefoselis Drugs 0.000 description 1
- QDUIJCOKQCCXQY-WHJQOFBOSA-N cefozopran Chemical compound N([C@@H]1C(N2C(=C(CN3C4=CC=CN=[N+]4C=C3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=NSC(N)=N1 QDUIJCOKQCCXQY-WHJQOFBOSA-N 0.000 description 1
- 229960002642 cefozopran Drugs 0.000 description 1
- DKOQGJHPHLTOJR-WHRDSVKCSA-N cefpirome Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 DKOQGJHPHLTOJR-WHRDSVKCSA-N 0.000 description 1
- 229960000466 cefpirome Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229940038704 clostridium perfringens Drugs 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- PKHFEGZZONAJBZ-JXXNUIPTSA-N corynecandin Natural products CCCCCC=C/C=C/C(=O)OCC1OC(OC2C(CO)OC(C(O)C2OC(=O)C(=CC=CCC(O)C(C)CC)C)c3c(O)cc(O)cc3CO)C(O)C(O)C1O PKHFEGZZONAJBZ-JXXNUIPTSA-N 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 108010083968 cyclothialidine Proteins 0.000 description 1
- HMHQWJDFNVJCHA-UHFFFAOYSA-N cyclothialidine Natural products O=C1NC(C(=O)NC(C)C(O)=O)CSCC2=C(O)C=C(O)C(C)=C2C(=O)OCC1NC(=O)C1C(O)CCN1C(=O)C(N)CO HMHQWJDFNVJCHA-UHFFFAOYSA-N 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 1
- 239000002019 doping agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 229950011561 epiroprim Drugs 0.000 description 1
- AUAHHJJRFHRVPV-BZDVOYDHSA-N ethambutol dihydrochloride Chemical compound [Cl-].[Cl-].CC[C@@H](CO)[NH2+]CC[NH2+][C@@H](CC)CO AUAHHJJRFHRVPV-BZDVOYDHSA-N 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- 229960002001 ethionamide Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 229940083579 fusidate sodium Drugs 0.000 description 1
- 229960004675 fusidic acid Drugs 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
- 239000013542 high molecular weight contaminant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229960002182 imipenem Drugs 0.000 description 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- GUCYBPFJNGVFEB-XELKFLSISA-N iseganan Chemical compound C([C@H]1C(=O)N[C@H]2CSSC[C@H](NC(=O)[C@H](CC=3C=CC=CC=3)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(N1)=O)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)C(C)C)C1=CC=C(O)C=C1 GUCYBPFJNGVFEB-XELKFLSISA-N 0.000 description 1
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000003835 ketolide antibiotic agent Substances 0.000 description 1
- MCNCNVGBSVXONP-PUJVZGPTSA-N khafrefungin Chemical compound CCCCCCCCCC[C@H](C)[C@@H](O)[C@@H](C)\C=C(/C)\C=C(/C)C(=O)[C@H](C)\C=C(/C)C(=O)O[C@H](CO)[C@@H](O)[C@H](O)C(O)=O MCNCNVGBSVXONP-PUJVZGPTSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229950011020 lenapenem Drugs 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 150000002646 long chain fatty acid esters Chemical class 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- JSWKNDSDVHJUKY-CYGWNLPQSA-N mersacidin Chemical compound C([C@@H](C(=O)N[C@@H]1[C@H](C)SC[C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)NC1=O)C(=O)N[C@@H]1[C@H](C)SC[C@H]2C(=O)N[C@H](C(N/C=C/S[C@@H](C)C(NC(=O)[C@H](CC(C)C)NC1=O)C(=O)NC(=C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)[C@H](C)CC)NC(=O)[C@H]1[C@@H](SC[C@H](N)C(=O)N1)C)C1=CC=CC=C1 JSWKNDSDVHJUKY-CYGWNLPQSA-N 0.000 description 1
- 108010067215 mersacidin Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 229960003900 methenamine hippurate Drugs 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 229960002159 micafungin Drugs 0.000 description 1
- PIEUQSKUWLMALL-YABMTYFHSA-N micafungin Chemical compound C1=CC(OCCCCC)=CC=C1C1=CC(C=2C=CC(=CC=2)C(=O)N[C@@H]2C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C2)[C@H](O)CC(N)=O)[C@H](O)[C@@H](O)C=2C=C(OS(O)(=O)=O)C(O)=CC=2)[C@@H](C)O)=O)=NO1 PIEUQSKUWLMALL-YABMTYFHSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000013048 microbiological method Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229960003128 mupirocin Drugs 0.000 description 1
- 229930187697 mupirocin Natural products 0.000 description 1
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 1
- OZGNYLLQHRPOBR-DHZHZOJOSA-N naftifine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)C\C=C\C1=CC=CC=C1 OZGNYLLQHRPOBR-DHZHZOJOSA-N 0.000 description 1
- 229960004313 naftifine Drugs 0.000 description 1
- 238000001728 nano-filtration Methods 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 1
- 229960001907 nitrofurazone Drugs 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 229940049547 paraxin Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 229960001589 posaconazole Drugs 0.000 description 1
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 description 1
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 229960000918 protionamide Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 1
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 1
- 229960000611 pyrimethamine Drugs 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- PMZDQRJGMBOQBF-UHFFFAOYSA-N quinolin-4-ol Chemical group C1=CC=C2C(O)=CC=NC2=C1 PMZDQRJGMBOQBF-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 229960002771 retapamulin Drugs 0.000 description 1
- SGHWBDUXKUSFOP-KYALZUAASA-N rifalazil Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)N=C2C(=O)C=3C(O)=C4C)C)OC)C4=C1C=3C(NC1=C(O)C=3)=C2OC1=CC=3N1CCN(CC(C)C)CC1 SGHWBDUXKUSFOP-KYALZUAASA-N 0.000 description 1
- 229950005007 rifalazil Drugs 0.000 description 1
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000011894 semi-preparative HPLC Methods 0.000 description 1
- 201000001223 septic arthritis Diseases 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 229940099992 seromycin Drugs 0.000 description 1
- 229960005429 sertaconazole Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 229960003177 sitafloxacin Drugs 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- OGGVRVMISBQNMQ-MDGIRFSOSA-N sordarin Chemical compound O[C@H]1[C@H](O)[C@H](OC)[C@@H](C)O[C@H]1OC[C@]1([C@@]2(C(C(C)C)=C3)C(O)=O)[C@H]3C[C@]2(C=O)[C@@H]2CC[C@@H](C)[C@H]2C1 OGGVRVMISBQNMQ-MDGIRFSOSA-N 0.000 description 1
- OGGVRVMISBQNMQ-UHFFFAOYSA-N sordarin Natural products OC1C(O)C(OC)C(C)OC1OCC1(C2(C(C(C)C)=C3)C(O)=O)C3CC2(C=O)C2CCC(C)C2C1 OGGVRVMISBQNMQ-UHFFFAOYSA-N 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- 229960000268 spectinomycin Drugs 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 229940037645 staphylococcus epidermidis Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000012859 sterile filling Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229940076156 streptococcus pyogenes Drugs 0.000 description 1
- 229940115922 streptococcus uberis Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 229950000153 sulopenem Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960002722 terbinafine Drugs 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- NWWZPOKUUAIXIW-UHFFFAOYSA-N thiamethoxam Chemical compound O=N(=O)N=C1N(C)COCN1CC1=CN=C(Cl)S1 NWWZPOKUUAIXIW-UHFFFAOYSA-N 0.000 description 1
- 229960003053 thiamphenicol Drugs 0.000 description 1
- OTVAEFIXJLOWRX-NXEZZACHSA-N thiamphenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl)C=C1 OTVAEFIXJLOWRX-NXEZZACHSA-N 0.000 description 1
- 239000012745 toughening agent Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 229940072335 vancocin Drugs 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 229960004740 voriconazole Drugs 0.000 description 1
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/145—Extraction; Separation; Purification by extraction or solubilisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/886—Streptomyces
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Compounds Of Unknown Constitution (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
杂质ID | 保留时间 | 观测的MW | LillyID | CubistID | HPLC总面积的% |
1 | 7.96 | 1638 | LY212218 | CB-131012 | >0.5%,<1.0% |
2 | 9.11 | 1638 | CB-131011 | <0.5%,>0.1% | |
3 | 11.54 | 745 | LY213928 | CB-131008 | >0.5%,<1.0% |
4 | 12.28 | 1624 | CB-131006 | <0.5%,>0.1% | |
5 | 13.10 | 1618 | 未知-1 | <0.5%,>0.1% | |
6 | 14.43 | 587 | LY213827 | CB-130989 | >0.5%,<1.0% |
7 | 14.43 | 1606 | CB-131005 | >0.5%,<1.0% | |
8 | 15.10 | 1620 | LY213846 | CB-131010 | >1.0%,<4.0% |
达托霉素 | 16.68 | 1620 | LY146032 | CB-109187 | >90% |
9 | 17.92 | 874 | 未知-2 | <0.5%,>0.1% | |
10 | 19.57 | 1810 | 未知-3 | <0.5%,>0.1% | |
11 | 19.57 | 1635 | 未知-4 | <0.5%,>0.1% | |
12 | 20.93 | 859 | CB-131009 | <0.5%,>0.1% | |
13 | 23.11 | 1602 | LY178480 | CB-130952 | >1.0,<4.0% |
14 | 24.53 | 1634 | LY109208 | CB-131078 | <0.1 |
Claims (23)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17717000P | 2000-01-20 | 2000-01-20 | |
US60/177,170 | 2000-01-20 | ||
US09/735,191 | 2000-11-28 | ||
US09/735,191 US6696412B1 (en) | 2000-01-20 | 2000-11-28 | High purity lipopeptides, Lipopeptide micelles and processes for preparing same |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN01805212A Division CN1404487A (zh) | 2000-01-20 | 2001-01-18 | 高纯度脂肽、脂肽胶束及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101240013A true CN101240013A (zh) | 2008-08-13 |
CN101240013B CN101240013B (zh) | 2012-05-23 |
Family
ID=26873002
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN01805212A Pending CN1404487A (zh) | 2000-01-20 | 2001-01-18 | 高纯度脂肽、脂肽胶束及其制备方法 |
CN201110133359.2A Expired - Lifetime CN102229650B (zh) | 2000-01-20 | 2001-01-18 | 高纯度脂肽、脂肽胶束及其制备方法 |
CN2012100807774A Pending CN102671181A (zh) | 2000-01-20 | 2001-01-18 | 高纯度脂肽、脂肽胶束及其制备方法 |
CN201710025711.8A Expired - Lifetime CN107082798B (zh) | 2000-01-20 | 2001-01-18 | 高纯度脂肽、脂肽胶束及其制备方法 |
CN200810087401XA Expired - Lifetime CN101240013B (zh) | 2000-01-20 | 2001-01-18 | 高纯度脂肽、脂肽胶束及其制备方法 |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN01805212A Pending CN1404487A (zh) | 2000-01-20 | 2001-01-18 | 高纯度脂肽、脂肽胶束及其制备方法 |
CN201110133359.2A Expired - Lifetime CN102229650B (zh) | 2000-01-20 | 2001-01-18 | 高纯度脂肽、脂肽胶束及其制备方法 |
CN2012100807774A Pending CN102671181A (zh) | 2000-01-20 | 2001-01-18 | 高纯度脂肽、脂肽胶束及其制备方法 |
CN201710025711.8A Expired - Lifetime CN107082798B (zh) | 2000-01-20 | 2001-01-18 | 高纯度脂肽、脂肽胶束及其制备方法 |
Country Status (25)
Country | Link |
---|---|
US (7) | US6696412B1 (zh) |
EP (6) | EP1252179B1 (zh) |
JP (2) | JP5303087B2 (zh) |
KR (4) | KR20110126737A (zh) |
CN (5) | CN1404487A (zh) |
AT (2) | ATE311405T1 (zh) |
AU (1) | AU784937B2 (zh) |
BR (1) | BRPI0107731B8 (zh) |
CA (2) | CA2743326C (zh) |
CY (2) | CY1109846T1 (zh) |
CZ (2) | CZ305004B6 (zh) |
DE (2) | DE60115383T2 (zh) |
DK (2) | DK2264047T3 (zh) |
ES (4) | ES2547281T3 (zh) |
HK (6) | HK1054240A1 (zh) |
HU (1) | HUP0203969A2 (zh) |
IL (3) | IL150733A0 (zh) |
IS (1) | IS6470A (zh) |
MX (1) | MXPA02007132A (zh) |
NO (1) | NO20023476L (zh) |
NZ (1) | NZ520324A (zh) |
PL (3) | PL226956B1 (zh) |
PT (2) | PT1586580E (zh) |
RU (1) | RU2311460C9 (zh) |
WO (1) | WO2001053330A2 (zh) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101777094B (zh) * | 2010-02-01 | 2011-11-16 | 天津大学 | 达托霉素生产菌玫瑰孢链霉菌的代谢网络分析方法 |
CN102276696A (zh) * | 2010-06-09 | 2011-12-14 | 上海来益生物药物研究开发中心有限责任公司 | 达托霉素的纯化方法 |
CN102325785A (zh) * | 2009-02-19 | 2012-01-18 | 埃克斯利亚制药有限公司 | 用于纯化脂肽的方法 |
CN103159829A (zh) * | 2011-12-08 | 2013-06-19 | 北大方正集团有限公司 | 达托霉素的提取方法 |
CN103224547A (zh) * | 2013-04-28 | 2013-07-31 | 华北制药集团新药研究开发有限责任公司 | 一种达托霉素的分离纯化方法 |
CN103724400A (zh) * | 2012-10-10 | 2014-04-16 | 北大方正集团有限公司 | 一种分离纯化脱水达托霉素的方法 |
CN104387444A (zh) * | 2014-11-13 | 2015-03-04 | 北大医药重庆大新药业股份有限公司 | 一种达托霉素杂质rs-2高纯度样品的制备方法 |
CN105001305A (zh) * | 2015-04-29 | 2015-10-28 | 利穗科技(苏州)有限公司 | 利用层析技术提取高纯度达托霉素的方法 |
CN110339342A (zh) * | 2018-04-03 | 2019-10-18 | 江苏恒瑞医药股份有限公司 | 一种达托霉素的盐或含盐的组合物及其制备方法 |
CN112898383A (zh) * | 2021-01-29 | 2021-06-04 | 深圳海创生物科技有限公司 | 一种寡肽、活性肽组合物及其在制备具有抗炎作用的产品中的应用 |
CN113004373A (zh) * | 2019-12-19 | 2021-06-22 | 鲁南制药集团股份有限公司 | 一种达托霉素的纯化方法 |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6696412B1 (en) | 2000-01-20 | 2004-02-24 | Cubist Pharmaceuticals, Inc. | High purity lipopeptides, Lipopeptide micelles and processes for preparing same |
CA2301336A1 (en) * | 2000-03-17 | 2001-09-17 | Michael T. Kelly | Topical treatment of rosacea |
US20060014674A1 (en) * | 2000-12-18 | 2006-01-19 | Dennis Keith | Methods for preparing purified lipopeptides |
NZ571597A (en) | 2000-12-18 | 2010-05-28 | Cubist Pharm Inc | Method for preparing crystalline and crystal-like forms of purified daptomycin lipopeptides |
EP1932853A1 (en) | 2001-08-06 | 2008-06-18 | Cubist Pharmaceutical Inc. | Novel depsipeptides and process for preparing same |
RU2348647C2 (ru) | 2001-08-06 | 2009-03-10 | Кьюбист Фармасьютикалз, Инк | Новые депсипептиды и способы их получения |
MXPA04011390A (es) * | 2002-05-16 | 2005-02-17 | Sepracor Inc | Aminas que inhiben un transportador de anandamida de mamifero, y metodos de uso de las mismas. |
US7317001B2 (en) | 2002-06-06 | 2008-01-08 | Oscient Pharmaceuticals Corporation | Use of ramoplanin to treat diseases associated with the use of antibiotics |
DE60330161D1 (de) * | 2002-08-29 | 2009-12-31 | Activbiotics Pharma Llc | Rifalazil zur behandlung von infektionen mit clostridium difficile |
US7145762B2 (en) * | 2003-02-11 | 2006-12-05 | Taser International, Inc. | Systems and methods for immobilizing using plural energy stores |
KR100554481B1 (ko) * | 2004-06-30 | 2006-03-03 | 씨제이 주식회사 | 반코마이신 염산염의 정제방법 |
JP2008534444A (ja) * | 2005-03-10 | 2008-08-28 | スミスクライン・ビーチャム・コーポレイション | 新規な方法 |
EP2018864A1 (en) | 2007-07-23 | 2009-01-28 | Biomet Deutschland GmbH | Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition |
EP3150617B1 (en) | 2007-11-21 | 2020-04-08 | Cipla USA, Inc. | Antibacterial aminoglycoside analogs |
WO2009143008A1 (en) * | 2008-05-21 | 2009-11-26 | Daedalus Innovations Llc | Solubilization of proteins in reverse micelles by extraction from a solid support |
WO2009144739A1 (en) * | 2008-05-26 | 2009-12-03 | Biocon Limited | Amorphous daptomycin and a method of purification thereof |
DE102008046610A1 (de) * | 2008-09-09 | 2010-03-11 | Biomet Deutschland Gmbh | Verwendung einer pharmazeutischen Zusammensetzung zur lokalen Infektionstherapie sowie Medizinprodukt |
CN101830970B (zh) * | 2009-03-12 | 2012-06-27 | 成都雅途生物技术有限公司 | 一种高纯度达托霉素(Daptomycin)的纯化制备方法 |
CN101899094B (zh) * | 2009-06-01 | 2012-11-21 | 安徽丰原发酵技术工程研究有限公司 | 一种高纯达托霉素的制备方法 |
WO2011002258A2 (ko) * | 2009-07-02 | 2011-01-06 | 한양대학교 산학협력단 | 아르기닌 기제 양친성 펩티드 마이셀 |
WO2011035108A1 (en) * | 2009-09-17 | 2011-03-24 | Eagle Pharmaceuticals, Inc. | Formulations of daptomycin |
CA2774094A1 (en) * | 2009-11-23 | 2011-05-26 | Eagle Pharmaceuticals, Inc. | Formulations of daptomycin |
HUE039967T2 (hu) | 2009-11-23 | 2019-02-28 | Cubist Pharmaceuticals Llc | Lipopeptid kompozíció és ezzel kapcsolatos eljárások |
KR101151878B1 (ko) * | 2010-06-08 | 2012-05-31 | 미원상사주식회사 | 지방산 트리펩타이드염 및 이를 함유하는 항균 조성물 |
RU2448725C2 (ru) * | 2010-07-13 | 2012-04-27 | Российская Федерация, От Имени Которой Выступает Министерство Образования И Науки Российской Федерации | Способ повышения бактерицидной активности |
CN101957348B (zh) * | 2010-09-17 | 2012-07-25 | 中华人民共和国珠海出入境检验检疫局 | 同时检测食品中氟喹诺酮类药物和氯霉素类药物的方法 |
KR200457763Y1 (ko) * | 2010-09-30 | 2012-01-02 | 상 택 임 | 형광등 낙하 방지 기능을 갖는 안전소켓 |
CA2823628A1 (en) | 2011-01-05 | 2012-07-12 | Hospira, Inc. | Spray drying vancomycin |
CN102206694B (zh) * | 2011-04-06 | 2013-10-16 | 山东新时代药业有限公司 | 一种含有癸酸的缓释组合物 |
WO2013012101A1 (ko) * | 2011-07-15 | 2013-01-24 | 미원상사주식회사 | 지방산 트리펩타이드염 및 이를 함유하는 항균 조성물 |
CN102492024A (zh) * | 2011-12-09 | 2012-06-13 | 厦门大学 | 从发酵液中提取达托霉素的方法 |
CN102675426B (zh) * | 2012-04-26 | 2013-12-11 | 杭州华东医药集团生物工程研究所有限公司 | 一种达托霉素的提取纯化方法 |
US9878054B2 (en) * | 2012-05-18 | 2018-01-30 | Tufts Medical Center, Inc. | Polypeptide and lipophilic moiety conjugate compositions, formulations, and uses related thereto |
US8809314B1 (en) | 2012-09-07 | 2014-08-19 | Cubist Pharmacueticals, Inc. | Cephalosporin compound |
NZ706286A (en) | 2012-09-11 | 2018-05-25 | Hospira Australia Pty Ltd | Daptomycin formulations and uses thereof |
CN103848894A (zh) * | 2012-11-30 | 2014-06-11 | 杨子剑 | 含有达托霉素结构的新化合物以及制备方法和用途 |
CN104043104B (zh) | 2013-03-15 | 2018-07-10 | 浙江创新生物有限公司 | 含盐酸万古霉素的喷雾干粉及其工业化制备方法 |
CN104511011A (zh) * | 2013-09-29 | 2015-04-15 | 山东新时代药业有限公司 | 一种达托霉素无菌粉末及其制备方法 |
CN104650189A (zh) * | 2013-11-19 | 2015-05-27 | 北大方正集团有限公司 | 一种异构达托霉素的制备方法 |
KR101601089B1 (ko) * | 2014-04-22 | 2016-03-09 | 주식회사 종근당바이오 | 신규한 답토마이신 생산 균주 및 이를 이용한 답토마이신의 제조방법 |
AU2015289602B2 (en) | 2014-07-17 | 2020-06-25 | Abbvie Inc. | High purity oritavancin and method of producing same |
KR101716879B1 (ko) * | 2014-11-19 | 2017-03-17 | 주식회사 종근당바이오 | 데카노일 글리세라이드를 이용한 답토마이신의 생산방법 |
AR100034A1 (es) | 2015-01-30 | 2016-09-07 | Consejo Nac De Investig Científicas Y Técnicas (Conicet) | Una composición farmacéutica soluble en agua que comprende, al menos, una sustancia terapéuticamente activa y, al menos, una sustancia con capacidad para formar micelas |
CN106866789A (zh) * | 2015-12-11 | 2017-06-20 | 北大方正集团有限公司 | 一种分离纯化达托霉素rs-8杂质的方法 |
CN106866791A (zh) * | 2015-12-11 | 2017-06-20 | 北大方正集团有限公司 | 一种高纯度达托霉素内酯水解物的制备方法 |
CN106866790A (zh) * | 2015-12-11 | 2017-06-20 | 北大方正集团有限公司 | 达托霉素RS-5/6、RS-7和RS-7a/7b杂质的制备方法 |
US10647746B2 (en) | 2016-04-08 | 2020-05-12 | Versitech Limited | Antibacterial cyclic lipopeptides |
US11667674B2 (en) | 2016-04-08 | 2023-06-06 | Versitech Limited | Antibacterial cyclic lipopeptides |
IT201600127655A1 (it) | 2016-12-16 | 2018-06-16 | Gnosis Spa | Processo per la purificazione di antibiotici lipopolipeptidici |
JP7138702B2 (ja) | 2017-09-22 | 2022-09-16 | ベクトン・ディキンソン・アンド・カンパニー | カテーテルロック溶液としての使用のための4%クエン酸三ナトリウム溶液 |
CN109589306A (zh) * | 2017-09-30 | 2019-04-09 | 上海交通大学医学院附属第九人民医院 | 脂质体在制备用于清除蛋白结合毒素的药物制剂中的用途 |
CN107817307B (zh) * | 2017-11-01 | 2020-12-25 | 重庆华邦制药有限公司 | Hplc法分离测定帕司烟肼及其相关杂质的方法 |
CN109828037B (zh) * | 2017-11-23 | 2021-11-23 | 中国科学院大连化学物理研究所 | 一种高通量富集和鉴定内源性n/o-连接糖肽的方法 |
WO2019133313A1 (en) * | 2017-12-28 | 2019-07-04 | Locus Ip Company, Llc | Oral health composition comprising purified biosurfactants and/or their derivatives |
PL237299B1 (pl) * | 2018-02-09 | 2021-04-06 | Boruta Zachem Biochemia Spolka Z Ograniczona Odpowiedzialnoscia | Sposób oczyszczania i/lub rozdzielania surfaktyny z wykorzystaniem Chromatografii Przeciwprądowej |
CN108333272A (zh) * | 2018-03-02 | 2018-07-27 | 重庆华邦胜凯制药有限公司 | Lc-msms法分离测定对氨基水杨酸及其相关杂质的方法 |
CN110577581A (zh) * | 2018-06-07 | 2019-12-17 | 美国蓝博药业公司 | 一种新型的抑菌脂肽化合物、制备方法及其应用 |
WO2020018888A1 (en) | 2018-07-20 | 2020-01-23 | The Board Of Regents Of The University Of Oklahoma | Antimicrobial peptides and methods of use |
CN113271922A (zh) * | 2018-12-21 | 2021-08-17 | 艾瑞克有限公司 | 新型组合物 |
CN111366644B (zh) * | 2018-12-25 | 2022-07-26 | 江苏先声药业有限公司 | 一种比阿培南侧链有关物质的hplc检测方法 |
CN109444294B (zh) * | 2018-12-27 | 2021-06-22 | 苏州莱奥生物技术有限公司 | 一种分离利奈唑胺和其手性异构体的高效液相色谱方法 |
CN109917047A (zh) * | 2019-04-15 | 2019-06-21 | 陕西科技大学 | 超高效液相色谱-四极杆飞行时间质谱法同时筛查鱼中多类别药物残留的方法 |
CN110146620B (zh) * | 2019-06-11 | 2022-04-19 | 福建医科大学孟超肝胆医院(福州市传染病医院) | 一种uplc-ms/ms法同时检测血浆中五种抗结核药物的方法 |
EP4117625A1 (en) | 2020-03-12 | 2023-01-18 | Baxter International Inc. | Daptomycin formulations containing a combination of sorbitol and mannitol |
CN113929743A (zh) * | 2020-06-29 | 2022-01-14 | 鲁南制药集团股份有限公司 | 一种制备达托霉素杂质rs-1和杂质rs-3的方法 |
CN113929747A (zh) * | 2020-06-29 | 2022-01-14 | 鲁南制药集团股份有限公司 | 一种制备达托霉素杂质RS-7a的方法 |
CN111892647B (zh) * | 2020-08-18 | 2022-04-29 | 丽珠集团福州福兴医药有限公司 | 一种提高达托霉素发酵产量的补料方法 |
CN112089823B (zh) * | 2020-09-25 | 2024-02-06 | 珠海中科先进技术研究院有限公司 | 一种短梗霉素a和制霉菌素组合物及其复合软膏、凝胶剂以及喷剂 |
CN112684043A (zh) * | 2020-12-16 | 2021-04-20 | 南京健友生化制药股份有限公司 | 一种达托霉素有关物质的检测方法 |
CN113866330B (zh) * | 2021-10-26 | 2023-08-22 | 丽珠集团福州福兴医药有限公司 | 一种脱水达托霉素的分离纯化方法和应用 |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US21978A (en) | 1858-11-02 | Trap for animals | ||
USRE21978E (en) | 1941-12-16 | Vacuum cleaner | ||
US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
USRE32333E (en) | 1978-10-16 | 1987-01-20 | Eli Lilly And Company | A-21978 Antibiotics and process for their production |
USRE32455E (en) | 1978-10-16 | 1987-07-07 | Eli Lilly And Company | A-21978 antibiotics and process for their production |
US4331594A (en) * | 1978-10-16 | 1982-05-25 | Eli Lilly And Company | A-21978 Antibiotics and process for their production |
EP0014815A3 (de) | 1978-12-20 | 1980-10-29 | Ciba-Geigy Ag | Peptidderivate, Verfahren zu deren Herstellung und Zwischenprodukte sowie pharmazeutische Präparate mit einer dieser Verbindungen |
IE55221B1 (en) | 1982-02-27 | 1990-07-04 | Beecham Group Plc | Antibacterial 1-normon-2-yl-heterocyclic compounds |
US4537717A (en) | 1982-05-21 | 1985-08-27 | Eli Lilly And Company | Derivatives of A-21978C cyclic peptides |
USRE32311E (en) | 1982-05-21 | 1986-12-16 | Eli Lilly And Company | Derivatives of A-21978C cyclic peptides |
USRE32310E (en) | 1982-05-21 | 1986-12-16 | Eli Lilly And Company | Derivatives of A-21978C cyclic peptides |
US4482487A (en) | 1982-05-21 | 1984-11-13 | Eli Lilly And Company | A-21978C cyclic peptides |
US4524135A (en) | 1982-05-21 | 1985-06-18 | Eli Lilly And Company | A-21978C cyclic peptides |
IL68700A0 (en) | 1982-05-21 | 1983-09-30 | Lilly Co Eli | Improvements relating to a-21978c cyclic peptide derivatives and their production |
US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
US4885243A (en) | 1984-10-09 | 1989-12-05 | Eli Lilly And Company | Process for producing A-21978C derivatives |
FI82075C (fi) | 1984-10-09 | 1991-01-10 | Lilly Co Eli | Foerfarande foer framstaellning av a-21978c-derivat och vid foerfarandet anvaend streptomyces roseosporus. |
US4800157A (en) | 1985-09-09 | 1989-01-24 | Eli Lilly And Company | Process for producing the A-21978C antibiotics |
US4865729A (en) | 1985-11-04 | 1989-09-12 | Sepragen Corporation | Radial thin layer chromatography |
US4840730A (en) | 1986-07-25 | 1989-06-20 | Sepragen Corporation | Chromatography system using horizontal flow columns |
US4708782A (en) | 1986-09-15 | 1987-11-24 | Sepragen Corporation | Chromatography column-electrophoresis system |
CA1319886C (en) | 1987-02-03 | 1993-07-06 | Alberto Ferro | Mixed micelle solutions |
US4874843A (en) | 1987-12-03 | 1989-10-17 | Eli Lilly And Company | Chromatographic purification process |
CA1315229C (en) | 1987-06-10 | 1993-03-30 | Patrick J. Baker | Chromatographic purification process |
EP0294990A3 (en) * | 1987-06-10 | 1990-05-09 | Eli Lilly And Company | Chromatographic purification process |
US5271935A (en) | 1988-02-05 | 1993-12-21 | Hoechst Aktiengesellschaft | Antibiotic, cammunocin, a process for the preparation thereof, and the use thereof as a pharmaceutical |
CA1337758C (en) | 1988-04-11 | 1995-12-19 | Eli Lilly And Company | Peptide antibiotics |
CA2011365A1 (en) * | 1989-03-06 | 1990-09-06 | Eugene L. Inman | Diluent formulation for daptomycin |
US5202309A (en) | 1989-06-30 | 1993-04-13 | Merck & Co., Inc. | Antibiotic cyclopeptide fermentation product |
EP0438813B1 (en) | 1990-01-26 | 1997-11-19 | Hoechst Aktiengesellschaft | A novel antibiotic, Deoxymulundocandin, a process for its production and its use as medicament |
DK0460882T3 (da) | 1990-06-07 | 1996-08-26 | Lilly Co Eli | Lipopeptiddeacylase |
JPH04167172A (ja) | 1990-10-31 | 1992-06-15 | Nec Corp | ベクトルプロセッサ |
JPH04224197A (ja) | 1990-12-26 | 1992-08-13 | Fujitsu Ltd | 生体高分子結晶化方法および装置 |
US5336756A (en) | 1991-05-01 | 1994-08-09 | Merck & Co., Inc. | Process for crystalline cyclic lipopeptides |
TW213468B (zh) | 1991-06-29 | 1993-09-21 | Hoechst Ag | |
JP3421338B2 (ja) | 1992-04-20 | 2003-06-30 | アボツト・ラボラトリーズ | バンコマイシンの製造方法 |
TW455591B (en) * | 1993-06-08 | 2001-09-21 | Hoechst Ag | Lipopeptides from actinoplanes sp. with pharmacological action, process for their production and the use thereof |
WO1995005384A1 (en) | 1993-08-13 | 1995-02-23 | Smithkline Beecham Plc | Derivatives of monic acids a and c having antibacterial, antimycoplasmatical, antifungal and herbicidal activity |
US5756680A (en) | 1994-01-05 | 1998-05-26 | Sepragen Corporation | Sequential separation of whey proteins and formulations thereof |
DE4411025A1 (de) | 1994-03-30 | 1995-10-05 | Hoechst Ag | Lipopeptid-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung |
IT1275427B (it) * | 1995-05-16 | 1997-08-07 | Bracco Spa | Processo per la depirogenazione di soluzioni farmaceutiche iniettabili |
US5955509A (en) | 1996-05-01 | 1999-09-21 | Board Of Regents, The University Of Texas System | pH dependent polymer micelles |
FR2755857B1 (fr) | 1996-11-19 | 1998-12-24 | Rhone Poulenc Rorer Sa | Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation |
FR2771640B1 (fr) | 1997-12-03 | 2000-02-11 | Inst Nat Sante Rech Med | Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire et leurs utilisations a des fins therapeutiques |
AU5528198A (en) | 1997-12-03 | 1999-06-16 | Immune Response Corporation, The | Vaccination and methods against multiple sclerosis using specific tcr vbeta peptides |
FR2772272B1 (fr) | 1997-12-16 | 2000-01-14 | Rhone Poulenc Rorer Sa | Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation |
WO1999055310A1 (en) | 1998-04-27 | 1999-11-04 | Altus Biologics Inc. | Stabilized protein crystals, formulations containing them and methods of making them |
FR2774687B1 (fr) * | 1998-02-06 | 2002-03-22 | Inst Nat Sante Rech Med | Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques |
DE19807972A1 (de) | 1998-02-25 | 1999-08-26 | Hoechst Marion Roussel De Gmbh | Lipopeptidantibiotika-Calciumsalze, Verfahren zu ihrer Herstellung und Verwendung |
EP1100947A4 (en) | 1998-08-07 | 2001-09-05 | Merck & Co Inc | PRODUCTION OF AN ANTIBIOTIC |
CA2344318C (en) | 1998-09-25 | 2006-07-04 | Cubist Pharmaceuticals, Inc. | Methods for administration of antibiotics |
US7408025B2 (en) | 1999-12-15 | 2008-08-05 | Cubist Pharmaceuticals, Inc. | Lipopeptides as antibacterial agents |
AU784942B2 (en) | 1999-12-15 | 2006-08-03 | Cubist Pharmaceuticals, Inc. | Daptomycin analogs and their use as antibacterial agents |
US6911525B2 (en) | 1999-12-15 | 2005-06-28 | Cubist Pharmaceuticals, Inc. | Lipopeptides as antibacterial agents |
US6696412B1 (en) | 2000-01-20 | 2004-02-24 | Cubist Pharmaceuticals, Inc. | High purity lipopeptides, Lipopeptide micelles and processes for preparing same |
US20060014674A1 (en) | 2000-12-18 | 2006-01-19 | Dennis Keith | Methods for preparing purified lipopeptides |
NZ571597A (en) | 2000-12-18 | 2010-05-28 | Cubist Pharm Inc | Method for preparing crystalline and crystal-like forms of purified daptomycin lipopeptides |
WO2002059145A1 (en) | 2000-12-18 | 2002-08-01 | Cubist Pharmaceuticals, Inc. | Methods for preparing purified lipopeptides |
KR20100039443A (ko) | 2001-08-06 | 2010-04-15 | 큐비스트 파마슈티컬즈 인코포레이티드 | 답토마이신 생합성 유전자 클러스터에 관련된 조성물 및 방법 |
US20030144362A1 (en) | 2002-01-28 | 2003-07-31 | Utterberg David S. | High viscosity antibacterials for cannulae |
US8912174B2 (en) | 2003-04-16 | 2014-12-16 | Mylan Pharmaceuticals Inc. | Formulations and methods for treating rhinosinusitis |
US20050074485A1 (en) | 2003-05-14 | 2005-04-07 | Lipton James M. | Anti-inflammatory/anti-microbial peptides for use in dialysis |
US8003673B2 (en) | 2005-05-31 | 2011-08-23 | Cubist Pharmaceuticals, Inc. | Daptomycin for the treatment of biofilm and catheter salvage |
US9393093B2 (en) | 2008-02-18 | 2016-07-19 | Covidien Lp | Clip for implant deployment device |
WO2011035108A1 (en) | 2009-09-17 | 2011-03-24 | Eagle Pharmaceuticals, Inc. | Formulations of daptomycin |
HUE039967T2 (hu) | 2009-11-23 | 2019-02-28 | Cubist Pharmaceuticals Llc | Lipopeptid kompozíció és ezzel kapcsolatos eljárások |
US9406568B2 (en) | 2014-11-21 | 2016-08-02 | International Business Machines Corporation | Semiconductor structure containing low-resistance source and drain contacts |
-
2000
- 2000-11-28 US US09/735,191 patent/US6696412B1/en not_active Expired - Lifetime
-
2001
- 2001-01-18 EP EP01903121A patent/EP1252179B1/en not_active Expired - Lifetime
- 2001-01-18 PT PT05015374T patent/PT1586580E/pt unknown
- 2001-01-18 DE DE60115383T patent/DE60115383T2/de not_active Expired - Lifetime
- 2001-01-18 ES ES10174862.2T patent/ES2547281T3/es not_active Expired - Lifetime
- 2001-01-18 NZ NZ520324A patent/NZ520324A/en not_active IP Right Cessation
- 2001-01-18 CN CN01805212A patent/CN1404487A/zh active Pending
- 2001-01-18 BR BRPI0107731A patent/BRPI0107731B8/pt not_active IP Right Cessation
- 2001-01-18 EP EP15173312.8A patent/EP2940034B1/en not_active Expired - Lifetime
- 2001-01-18 DK DK10174862.2T patent/DK2264047T3/en active
- 2001-01-18 KR KR1020117023193A patent/KR20110126737A/ko not_active Application Discontinuation
- 2001-01-18 ES ES15173312T patent/ES2799702T3/es not_active Expired - Lifetime
- 2001-01-18 EP EP10174862.2A patent/EP2264047B1/en not_active Expired - Lifetime
- 2001-01-18 AT AT01903121T patent/ATE311405T1/de active
- 2001-01-18 PL PL400575A patent/PL226956B1/pl unknown
- 2001-01-18 EP EP09014616A patent/EP2159229A1/en not_active Withdrawn
- 2001-01-18 DE DE60140631T patent/DE60140631D1/de not_active Expired - Lifetime
- 2001-01-18 JP JP2001553802A patent/JP5303087B2/ja not_active Expired - Lifetime
- 2001-01-18 AT AT05015374T patent/ATE449785T1/de active
- 2001-01-18 DK DK05015374.1T patent/DK1586580T3/da active
- 2001-01-18 CN CN201110133359.2A patent/CN102229650B/zh not_active Expired - Lifetime
- 2001-01-18 KR KR1020027009279A patent/KR101174140B1/ko active IP Right Grant
- 2001-01-18 CN CN2012100807774A patent/CN102671181A/zh active Pending
- 2001-01-18 CZ CZ2002-2830A patent/CZ305004B6/cs not_active IP Right Cessation
- 2001-01-18 CZ CZ2012-332A patent/CZ307877B6/cs not_active IP Right Cessation
- 2001-01-18 EP EP05015374A patent/EP1586580B1/en not_active Expired - Lifetime
- 2001-01-18 PT PT101748622T patent/PT2264047E/pt unknown
- 2001-01-18 KR KR1020127011479A patent/KR101291494B1/ko active IP Right Grant
- 2001-01-18 CN CN201710025711.8A patent/CN107082798B/zh not_active Expired - Lifetime
- 2001-01-18 EP EP15173324.3A patent/EP2940036B1/en not_active Expired - Lifetime
- 2001-01-18 ES ES05015374T patent/ES2336336T3/es not_active Expired - Lifetime
- 2001-01-18 PL PL356898A patent/PL214000B1/pl unknown
- 2001-01-18 HU HU0203969A patent/HUP0203969A2/hu unknown
- 2001-01-18 IL IL15073301A patent/IL150733A0/xx unknown
- 2001-01-18 CN CN200810087401XA patent/CN101240013B/zh not_active Expired - Lifetime
- 2001-01-18 CA CA2743326A patent/CA2743326C/en not_active Expired - Lifetime
- 2001-01-18 PL PL416764A patent/PL236352B1/pl unknown
- 2001-01-18 ES ES15173324T patent/ES2799706T3/es not_active Expired - Lifetime
- 2001-01-18 AU AU30978/01A patent/AU784937B2/en not_active Expired
- 2001-01-18 WO PCT/US2001/001748 patent/WO2001053330A2/en active Application Filing
- 2001-01-18 RU RU2002122114/13A patent/RU2311460C9/ru active
- 2001-01-18 KR KR1020077008648A patent/KR20070044079A/ko not_active Application Discontinuation
- 2001-01-18 CA CA2398726A patent/CA2398726C/en not_active Expired - Lifetime
- 2001-01-18 MX MXPA02007132A patent/MXPA02007132A/es active IP Right Grant
-
2002
- 2002-07-12 IS IS6470A patent/IS6470A/is unknown
- 2002-07-19 NO NO20023476A patent/NO20023476L/no not_active Application Discontinuation
-
2003
- 2003-09-11 HK HK03106508.9A patent/HK1054240A1/zh unknown
- 2003-12-29 US US10/747,485 patent/US20050009747A1/en not_active Abandoned
-
2006
- 2006-04-19 HK HK06104688.3A patent/HK1085746A1/xx not_active IP Right Cessation
-
2007
- 2007-04-24 US US11/739,180 patent/US8058238B2/en not_active Expired - Fee Related
-
2009
- 2009-02-12 HK HK09101340.6A patent/HK1120528A1/xx not_active IP Right Cessation
-
2010
- 2010-02-19 CY CY20101100167T patent/CY1109846T1/el unknown
- 2010-09-22 US US12/888,233 patent/US8129342B2/en not_active Expired - Fee Related
-
2011
- 2011-06-07 HK HK11105628.6A patent/HK1151546A1/zh not_active IP Right Cessation
-
2012
- 2012-02-16 US US13/398,219 patent/US8604164B2/en not_active Expired - Fee Related
- 2012-05-20 IL IL219889A patent/IL219889A/en active IP Right Grant
-
2013
- 2013-05-07 JP JP2013097659A patent/JP5631439B2/ja not_active Expired - Lifetime
- 2013-05-29 IL IL226636A patent/IL226636A/en active IP Right Grant
- 2013-06-14 US US13/918,083 patent/US8853357B2/en not_active Expired - Fee Related
-
2014
- 2014-09-02 US US14/475,319 patent/US9358267B2/en not_active Expired - Fee Related
-
2015
- 2015-09-22 CY CY20151100831T patent/CY1116827T1/el unknown
-
2016
- 2016-04-29 HK HK16104932.5A patent/HK1217205A1/zh unknown
- 2016-04-29 HK HK16104925.4A patent/HK1217204A1/zh unknown
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102325785A (zh) * | 2009-02-19 | 2012-01-18 | 埃克斯利亚制药有限公司 | 用于纯化脂肽的方法 |
CN102325785B (zh) * | 2009-02-19 | 2015-01-21 | 埃克斯利亚制药有限公司 | 用于纯化脂肽的方法 |
CN101777094B (zh) * | 2010-02-01 | 2011-11-16 | 天津大学 | 达托霉素生产菌玫瑰孢链霉菌的代谢网络分析方法 |
CN102276696B (zh) * | 2010-06-09 | 2014-11-05 | 上海来益生物药物研究开发中心有限责任公司 | 达托霉素的纯化方法 |
CN102276696A (zh) * | 2010-06-09 | 2011-12-14 | 上海来益生物药物研究开发中心有限责任公司 | 达托霉素的纯化方法 |
CN103159829A (zh) * | 2011-12-08 | 2013-06-19 | 北大方正集团有限公司 | 达托霉素的提取方法 |
CN103159829B (zh) * | 2011-12-08 | 2014-11-05 | 北大方正集团有限公司 | 达托霉素的提取方法 |
CN103724400B (zh) * | 2012-10-10 | 2015-12-16 | 北大方正集团有限公司 | 一种分离纯化脱水达托霉素的方法 |
CN103724400A (zh) * | 2012-10-10 | 2014-04-16 | 北大方正集团有限公司 | 一种分离纯化脱水达托霉素的方法 |
CN103224547B (zh) * | 2013-04-28 | 2015-05-20 | 华北制药集团新药研究开发有限责任公司 | 一种达托霉素的分离纯化方法 |
CN103224547A (zh) * | 2013-04-28 | 2013-07-31 | 华北制药集团新药研究开发有限责任公司 | 一种达托霉素的分离纯化方法 |
CN104387444A (zh) * | 2014-11-13 | 2015-03-04 | 北大医药重庆大新药业股份有限公司 | 一种达托霉素杂质rs-2高纯度样品的制备方法 |
CN105001305A (zh) * | 2015-04-29 | 2015-10-28 | 利穗科技(苏州)有限公司 | 利用层析技术提取高纯度达托霉素的方法 |
CN110339342A (zh) * | 2018-04-03 | 2019-10-18 | 江苏恒瑞医药股份有限公司 | 一种达托霉素的盐或含盐的组合物及其制备方法 |
CN113004373A (zh) * | 2019-12-19 | 2021-06-22 | 鲁南制药集团股份有限公司 | 一种达托霉素的纯化方法 |
CN112898383A (zh) * | 2021-01-29 | 2021-06-04 | 深圳海创生物科技有限公司 | 一种寡肽、活性肽组合物及其在制备具有抗炎作用的产品中的应用 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101240013B (zh) | 高纯度脂肽、脂肽胶束及其制备方法 | |
CN1982330A (zh) | 制备纯化脂肽的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1120528 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1120528 Country of ref document: HK |
|
C56 | Change in the name or address of the patentee | ||
CP03 | Change of name, title or address |
Address after: new jersey Patentee after: Qiubi Munster pharmaceutical limited liability company Address before: Massachusetts USA Patentee before: Cubist Pharmaceuticals, Inc. |
|
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: Luzern, Switzerland Patentee after: Qiubi Munster pharmaceutical limited liability company Address before: new jersey Patentee before: Qiubi Munster pharmaceutical limited liability company |
|
CX01 | Expiry of patent term |
Granted publication date: 20120523 |
|
CX01 | Expiry of patent term |